MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.13576

Медицинская библиотека · British journal of haematology · 2015

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Symeonidis Argiris, van Biezen Anja, de Wreede Liesbeth, Piciocchi Alfonso, Finke Juergen, Beelen Dietrich, Bornhäuser Martin, Cornelissen Jan, Volin Liisa, Mufti Ghulam, Chalandon Yves, Ganser Arnold, Bruno Benedetto, Niederwieser Dietger, Kobbe Guido, Schwerdtfeger Rainer, de Witte Theo, Robin Marie, Kröger Nicolaus, Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

СтатьяПеревод в очереди

Аннотация

The results of allogeneic stem cell transplantation (allo-SCT) in chronic myelomonocytic leukaemia (CMML) are usually reported together with other categories of myelodysplastic syndrome. We analysed transplantation outcome in 513 patients with CMML, with a median age of 53 years reported to the European Group for Blood and Marrow Transplantation. Conditioning was standard (n = 249) or reduced-intensity (n = 226). Donors were human leucocyte antigen-related (n = 285) or unrelated (n = 228). Disease status at transplantation was complete remission (CR) in 122 patients, no CR in 344, and unknown in 47. Engraftment was successful in 95%. Grades 2-4 acute graft-versus-host disease (GvHD) occurred in 33% of the patients and chronic GvHD was reported in 24%. The 4-year cumulative incidence of non-relapse mortality was 41% and 32% for relapse, resulting in a 4-year estimated relapse-free and overall survival (OS) of 27% and 33%, respectively. Patients transplanted in CR had lower probability for non-relapse death (P = 0·002) and longer relapse-free and OS (P = 0·001 and P = 0·005, respectively). In multivariate analysis the only significant prognostic factor for survival was the presence of CR at transplantation (P = 0·005). Allo-SCT remains a curative treatment option for patients with CMML and should preferably be performed early after diagnosis or after establishing the best possible remission status.

Для цитирования: Symeonidis Argiris, van Biezen Anja, de Wreede Liesbeth, Piciocchi Alfonso, Finke Juergen, Beelen Dietrich, Bornhäuser Martin, Cornelissen Jan, Volin Liisa, Mufti Ghulam, Chalandon Yves, Ganser Arnold, Bruno Benedetto, Niederwieser Dietger, Kobbe Guido, Schwerdtfeger Rainer, de Witte Theo, Robin Marie, Kröger Nicolaus, Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.. British journal of haematology. 2015. DOI: 10.1111/bjh.13576.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.